Hong Kong Drug Licence Applications and Acquisitions · RGYS|Global Licensing and Compliance Service Provider
Hong Kong pharmaceutical compliance · applications / acquisitions / ongoing maintenance Independent Third-Party Service Provider
HONG KONG DRUG LICENSING

For medicines requiring cold chain transport, what are the key quality control points throughout the process from receipt and storage to dispatch?

A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.

Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.

Drug Office, Department of Health Chinese Medicines Board

Q310 · Category G: Quality management and compliance systems (Q301–Q350)
Cold-chain medicine management is a major focus of GDP and requires the specified temperature (usually 2-8°C) to be maintained without interruption throughout the supply chain. Key quality control points apply throughout. On receipt: immediately check the temperature data logger in the refrigerated container or vehicle to confirm that temperatures did not exceed the limits during transport, and check the outer packaging for signs of condensation or frost. During storage: use a dedicated cold room or refrigerator that has undergone temperature mapping and is continuously monitored, with an audible and visual alarm system and backup power. On dispatch: use validated insulated shippers and coolants, selecting the packaging configuration according to the estimated transport time and external ambient temperature. At handover, ensure that the recipient can transfer the medicines immediately to compliant refrigeration equipment.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products has a dedicated and stringent chapter on handling temperature-sensitive medicines. Equipment, procedures and records must all demonstrate the ability to maintain cold chain integrity.

📗 Drew Tang's recommendations

We strongly recommend that clients conduct rigorous Performance Qualification (PQ) studies of the refrigerated packaging solutions they use, to ensure that the specified temperature is maintained even under simulated worst-case conditions (such as high summer temperatures and transport delays). Include a separate temperature data logger with every cold-chain shipment and require the customer to return the data to you on receipt, creating a closed-loop validation process. Specialised training for all staff handling cold-chain medicines is essential.

📕 Risk notice

Any cold-chain interruption could cause an entire batch of expensive biological products or vaccines to become ineffective, resulting in substantial financial loss. More seriously, using ineffective medicines could cause irreversible harm to patients. Regulators apply a zero-tolerance policy to cold-chain management deficiencies. Failure to provide complete, uninterrupted temperature records is a serious breach that may be sufficient grounds for licence suspension or revocation.

Back to Category G: Quality Management and Compliance Systems (Q301-Q350) Search more questions

YOUR NEXT STEP

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang

Business Manager Tang Shangyong (Drew Tang) will review your products, operating model, licence type and preparation requirements with you one-to-one. The precise service scope is confirmed in writing; pharmaceutical duties are carried out by legally qualified personnel, and approvals are determined by the competent authorities.

Book a Project Assessment ↗